{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:40Z","timestamp":1792099600353,"version":"4.4.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The purpose of the current study is to investigate the bactericidal effect of macrolides and \u03b2-lactams on <jats:italic toggle=\"yes\">Bordetella pertussis<\/jats:italic> (<jats:italic toggle=\"yes\">B. pertussis<\/jats:italic>) in the nasopharynx and provide guidance for treating macrolides-resistant <jats:italic toggle=\"yes\">B. pertussis<\/jats:italic> infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with whooping cough was diagnosed by culture of nasopharynx swabs between January 2016 to December 2018. <jats:italic toggle=\"yes\">B. pertussis<\/jats:italic> was identified using specific antisera against pertussis and parapertussis. Drug susceptibility test was carried out using the E-test method. The clearance of <jats:italic toggle=\"yes\">B. pertussis<\/jats:italic> in nasopharynx at 7 and 14 days into and posttreatment with macrolides, and \u03b2-lactams was compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 125 <jats:italic toggle=\"yes\">B. pertussis<\/jats:italic> samples were collected from patients who received single antibiotic treatment. Among those isolates, 62.4% (78\/125) had high resistance with minimum inhibitory concentrations greater than 256 mg\/L for erythromycin and azithromycin. The MIC<jats:sub>90<\/jats:sub> of piperacillin, cefoperazone-sulbactam, meropenem, ampicillin, ceftriaxone, ceftazidime and trimethoprim-sulfamethoxazole for these isolates was &lt;0.016, 0.094, 0.094, 0.19, 0.19, 0.25 and 0.75 mg\/L, respectively. The clearance rate with \u03b2-lactams treatment (68.8%, 44\/64) was significantly higher than that with macrolides treatment at 14 days posttreatment (50.8%, 31\/61) (\u03c7<jats:sup>2<\/jats:sup> = 4.18, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04). Macrolides had a better clearance rate at 7 days posttreatment than \u03b2-lactams (\u03c7<jats:sup>2<\/jats:sup> = 4.49, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03) for macrolides-sensitive isolates and a worse clearance rate for macrolides-resistant isolates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">B. pertussis<\/jats:italic> isolates had a high-resistant rate for macrolides in our study. Macrolides are the first choice for treating pertussis caused by macrolides-sensitive strains, and some \u03b2-lactams such as piperacillin should be considered as alternative antibiotics for treatment of macrolides-resistant <jats:italic toggle=\"yes\">B. pertussis<\/jats:italic> infection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002911","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T06:05:14Z","timestamp":1601964314000},"page":"87-90","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":27,"title":["Effect of Macrolides and \u03b2-lactams on Clearance of Bordetella pertussis in the Nasopharynx in Children With Whooping Cough"],"prefix":"10.1097","volume":"40","author":[{"given":"Yu-Mei","family":"Mi","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Zhen","family":"Hua","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Juan","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ping","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo-Na","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cid\/ciw051","article-title":"Protective effect of contemporary pertussis vaccines: a systematic review and meta-analysis.","volume":"62","author":"Fulton","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1097\/INF.0000000000000795","article-title":"Pertussis across the globe: recent epidemiologic trends from 2000 to 2013.","volume":"34","author":"Tan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R3-20250615","first-page":"91","article-title":"Eight-year review of Bordetella pertussis testing reveals seasonal pattern in the United States.","volume":"6","author":"Bhatti","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1017\/S0950268897008571","article-title":"Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis.","volume":"120","author":"Dodhia","year":"1998","journal-title":"Epidemiol Infect"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/civ472","article-title":"Risk factors associated with infant deaths from pertussis: a case-control study.","volume":"61","author":"Winter","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.prrv.2008.05.010","article-title":"Pertussis: review of epidemiology, diagnosis, management and prevention.","volume":"9","author":"Wood","year":"2008","journal-title":"Paediatr Respir Rev"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/QCO.0000000000000264","article-title":"Bordetella pertussis: new concepts in pathogenesis and treatment.","volume":"29","author":"Carbonetti","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12519-019-00308-5","article-title":"Clinical characteristics, molecular epidemiology and antimicrobial susceptibility of pertussis among children in southern China.","volume":"16","author":"Zhang","year":"2020","journal-title":"World J Pediatr"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/INF.0000000000002160","article-title":"Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: clinical features, genotype variations of antigenic genes and macrolides resistance.","volume":"38","author":"Fu","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3201\/eid2512.181836","article-title":"High prevalence of macrolide-resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014-2016.","volume":"25","author":"Li","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jgar.2019.01.029","article-title":"In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin\/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: a single-centre study in Zhejiang Province, China.","volume":"18","author":"Hua","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00006454-199203000-00003","article-title":"Erythromycin Study Group: comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis.","volume":"16","author":"Hoppe","year":"1992","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00006454-198511000-00003","article-title":"Pertussis: current status of prevention and treatment.","volume":"4","author":"Bass","year":"1985","journal-title":"Pediatr Infect Dis"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00006454-198601000-00051","article-title":"Erythromycin for treatment and prevention of pertussis.","volume":"5","author":"Bass","year":"1986","journal-title":"Pediatr Infect Dis"},{"issue":"RR-10","key":"R15-20250615","first-page":"1","article-title":"Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"40","year":"1991","journal-title":"MMWR Recomm Rep"},{"issue":"RR-14","key":"R16-20250615","first-page":"1","article-title":"Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.","volume":"54","author":"Tiwari","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF02962373","article-title":"State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.","volume":"26","author":"Hoppe","year":"1998","journal-title":"Infection"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:04:44Z","timestamp":1750003484000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002911","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,22]]}}}